ADCT vs. AMRN, ANRO, HROW, CRBP, ERAS, MREO, RANI, TERN, MRSN, and ANNX
Should you be buying ADC Therapeutics stock or one of its competitors? The main competitors of ADC Therapeutics include Amarin (AMRN), Alto Neuroscience (ANRO), Harrow (HROW), Corbus Pharmaceuticals (CRBP), Erasca (ERAS), Mereo BioPharma Group (MREO), Rani Therapeutics (RANI), Terns Pharmaceuticals (TERN), Mersana Therapeutics (MRSN), and Annexon (ANNX). These companies are all part of the "pharmaceutical preparations" industry.
Amarin (NASDAQ:AMRN) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, community ranking, risk and media sentiment.
22.3% of Amarin shares are owned by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are owned by institutional investors. 2.0% of Amarin shares are owned by company insiders. Comparatively, 35.4% of ADC Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, ADC Therapeutics had 16 more articles in the media than Amarin. MarketBeat recorded 19 mentions for ADC Therapeutics and 3 mentions for Amarin. ADC Therapeutics' average media sentiment score of 0.23 beat Amarin's score of 0.23 indicating that Amarin is being referred to more favorably in the media.
Amarin has higher revenue and earnings than ADC Therapeutics. Amarin is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.
Amarin currently has a consensus price target of $1.08, indicating a potential upside of 27.08%. ADC Therapeutics has a consensus price target of $7.25, indicating a potential upside of 68.60%. Given Amarin's stronger consensus rating and higher possible upside, analysts plainly believe ADC Therapeutics is more favorable than Amarin.
Amarin has a beta of 1.96, indicating that its stock price is 96% more volatile than the S&P 500. Comparatively, ADC Therapeutics has a beta of 1.69, indicating that its stock price is 69% more volatile than the S&P 500.
Amarin has a net margin of -18.96% compared to Amarin's net margin of -330.17%. ADC Therapeutics' return on equity of -9.48% beat Amarin's return on equity.
Amarin received 791 more outperform votes than ADC Therapeutics when rated by MarketBeat users. Likewise, 74.45% of users gave Amarin an outperform vote while only 64.56% of users gave ADC Therapeutics an outperform vote.
Summary
Amarin beats ADC Therapeutics on 10 of the 18 factors compared between the two stocks.
Get ADC Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ADC Therapeutics Competitors List
Related Companies and Tools
